Abstract
International guidelines recommend the use of Regorafenib or TAS 102 from third line of treatment in metastatic colorectal cancer (mCRC). Retrospective analysis revealed no outcome differences between these two drugs in pretreated mCRC patients. Previous studies found significant muscle mass loss (MML) during treatment with Regorafenib, unlike with TAS-102, probably due to different toxicity profiles. The aim of our study is to analyze the prognostic role of basal sarcopenia and low basal muscle attenuation (MA), representing fat infiltration of muscles, in mCRC patients in third-line treatment with Regorafenib or TAS102 and the correlation between type of third-line therapy and MML >5% at first CT assessment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
